GlassScriptPhysician profile
Chen-Pang Soong
NPI 1134549009
$7,745.12
in general payments reported to CMS, 2019-2025
38 companies · $2,469 in 2025
The $2,469 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $143 · 2021: $1,001 · 2022: $1,568 · 2023: $1,034 · 2024: $1,180 · 2025: $2,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,182 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,182.14 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,825.79 | 2021-2022 | |
| Stryker Corporation | $1,805.84 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Flowtriever |
| Inari Medical, INC. | $696.18 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boston Scientific Corporation | $333.54 | 2019-2024 | Avvigo Guidance System, Emerge Push, Opticross |
| Edwards Lifesciences Corporation | $319.26 | 2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $248.01 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $216.81 | 2020-2025 | Camzyos, Eliquis |
| Angiodynamics, INC. | $191.40 | 2024-2025 | Alphavac, Angiovac |
| Abiomed | $179.63 | 2020-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $165.84 | 2019-2023 | Lifevest |
| Corindus INC. | $148.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $128.71 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $122.16 | 2023-2024 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $121.19 | 2023-2025 | Amvuttra |
| Recor Medical INC | $120.76 | 2024 | Paradise Renal Denervation System |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $117.56 | 2023 | |
| Genzyme Corporation | $102.38 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $88.74 | 2022-2023 | Arcalyst |
| Astellas Pharma US INC | $69.99 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $68.70 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $61.85 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $59.92 | 2023-2024 | Xarelto |
| Philips North America LLC | $53.92 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $51.91 | 2023-2025 | Evkeeza, Praluent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.35 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $50.24 | 2025 | Verquvo |
| Heartflow, INC. | $44.80 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $36.57 | 2025 | Optimizer |
| Pfizer INC. | $36.45 | 2024-2025 | |
| Irhythm Technologies, INC. | $33.82 | 2023 | Zio Xt Patch |
| Inspire Medical Systems, INC. | $32.50 | 2025 | Inspire |
| Daiichi Sankyo INC. | $29.31 | 2023 | Injectafer |
| Medtronic, INC. | $25.81 | 2024 | Concertotm |
| Shockwave Medical, INC | $23.68 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novo Nordisk INC | $23.31 | 2024 | Ozempic, Rybelsus |
| Bridgebio Pharma, INC. | $21.49 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $21.40 | 2025 | Nexletol |
| Baxter Healthcare | $15.52 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen-Pang Soong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.